AbbVie Inc. (NYSE:ABBV – Get Free Report) was up 1.6% during trading on Thursday . The company traded as high as $255.31 and last traded at $254.9960. Approximately 4,392,954 shares changed hands during trading, a decline of 34% from the average session volume of 6,649,387 shares. The stock had previously closed at $250.91.
Key Stories Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie reported positive Phase 3 LUNA results for atogepant in the prevention of menstrual migraine. The treatment met the study’s primary goal and showed efficacy and safety, potentially supporting an additional growth opportunity for the migraine portfolio. AbbVie’s migraine treatment meets late-stage study goal
- Positive Sentiment: The LUNA data reinforces AbbVie’s position in migraine care and could expand the commercial potential of atogepant, adding another source of growth as Humira sales decline. AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results
- Positive Sentiment: HSBC raised its AbbVie price target to $315 from $300 while maintaining a Buy rating, signaling increased confidence in the company’s earnings outlook and pipeline. HSBC Adjusts Price Target on AbbVie
- Positive Sentiment: Skyrizi and Rinvoq continue to drive immunology growth, while new indications, partnerships and acquisitions—including the Apogee Therapeutics transaction—are intended to build AbbVie’s next wave of products. AbbVie’s Immunology Franchise
- Positive Sentiment: AbbVie declared a quarterly cash dividend of $1.73 per share, supporting the stock’s income appeal and indicating continued confidence in cash generation. AbbVie Declares Quarterly Dividend
- Neutral Sentiment: Analyst commentary highlights AbbVie’s successful transition away from Humira toward newer immunology products, but also raises questions about whether future growth is becoming too dependent on Skyrizi and Rinvoq. AbbVie vs. Novo Nordisk
- Negative Sentiment: The FDA issued a complete response letter for the fast-acting neurotoxin trenibotE, delaying or complicating a potential product launch and adding regulatory risk to AbbVie’s aesthetics pipeline. FDA Issues Complete Response Letter for TrenibotE
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the stock. UBS Group increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Cantor Fitzgerald lifted their target price on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Finally, BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $276.64.
AbbVie Stock Up 1.6%
The firm has a market capitalization of $450.52 billion, a price-to-earnings ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. The stock has a 50 day moving average of $254.66 and a 200 day moving average of $230.55.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company posted $2.97 EPS. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.
AbbVie Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.
Insider Transactions at AbbVie
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On AbbVie
Several hedge funds and other institutional investors have recently modified their holdings of ABBV. Rench Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter worth about $215,000. Miramontes Capital LLC boosted its stake in AbbVie by 2.9% during the 2nd quarter. Miramontes Capital LLC now owns 3,668 shares of the company’s stock valued at $923,000 after purchasing an additional 104 shares during the period. Capstone Financial Advisors Inc. boosted its stake in AbbVie by 1.4% during the 2nd quarter. Capstone Financial Advisors Inc. now owns 3,914 shares of the company’s stock valued at $985,000 after purchasing an additional 55 shares during the period. Tortoise Investment Management LLC grew its position in AbbVie by 7.6% in the 2nd quarter. Tortoise Investment Management LLC now owns 1,128 shares of the company’s stock worth $284,000 after purchasing an additional 80 shares during the last quarter. Finally, Community Bank of Raymore increased its stake in shares of AbbVie by 2.0% in the second quarter. Community Bank of Raymore now owns 12,673 shares of the company’s stock valued at $3,189,000 after purchasing an additional 250 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Featured Articles
- Five stocks we like better than AbbVie
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
